Corticosteroid effects on COPD alveolar macrophages: Dependency on cell culture methodology

Journal of Immunological Methods

Volumn 405, Issue , 2014, Pages 144-153

  Higham, Andrew ^a   Lea, Simon ^a   Ray, David ^a   Singh, Dave ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alveolar macrophage; Chronic obstructive pulmonary disease; Corticosteroids; Cytokines; Inflammation; P38 MAPK

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DORAMAPIMOD; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE TECHNIQUE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; WESTERN BLOTTING;

ALVEOLAR MACROPHAGE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CORTICOSTEROIDS; CYTOKINES; INFLAMMATION; P38 MAPK;

AGED; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRAZOLES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897454845     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.02.003     Document Type: Article

References (30)

1. Aikawa R., Nagai T., Kudoh S., Zou Y., Tanaka M., Tamura M., Akazawa H., Takano H., Nagai R., Komuro I. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 2002, 39:233.
2. Armstrong J., Sargent C., Singh D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin. Exp. Immunol. 2009, 158:74.
3. Armstrong J., Harbron C., Lea S., Booth G., Cadden P., Wreggett K.A., Singh D. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2011, 338:732.
4. Bourbeau J., Christodoulopoulos P., Maltais F., Yamauchi Y., Olivenstein R., Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62:938.
5. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., Yates J.C., Vestbo J., for the TORCH Investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007, 356:775.
6. Cosio B.G., Tsaprouni L., Ito K., Jazrawi E., Adcock I.M., Barnes P.J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004, 200:689.
7. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E., Donnelly L.E., Barnes P.J. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003, 167:24.
8. Denkert C., Warskulat U., Hensel F., Haussinger D. Osmolyte strategy in human monocytes and macrophages: involvement of p38MAPK in hyperosmotic induction of betaine and myoinositol transporters. Arch. Biochem. Biophys. 1998, 354:172.
9. Gaffey K., Reynolds S., Plumb J., Kaur M., Singh D. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur. Respir. J. 2013, 42:28.
10. GOLD Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2013, vol. 2013.
11. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23.
12. Gordon S.B., Read R.C. Macrophage defences against respiratory tract infections. Br. Med. Bull. 2002, 61:45.
13. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953.
14. Higham A., Lea S., Plumb J., Maschera B., Simpson K., Ray D., Singh D. The role of the liver X receptor in chronic obstructive pulmonary disease. Respir. Res. 2013, 14:106.
15. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., Cherniack R.M., Rogers R.M., Sciurba F.C., Coxson H.O., Pare P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350:2645.
16. Kaur M., Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. J. Pharmacol. Exp. Ther. 2013, 347:173.
17. Keatings V.M., Collins P.D., Scott D.M., Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996, 153:530.
18. Lea S., Plumb J., Metcalfe H., Spicer D., Woodman P., Fox J.C., Singh D. The effect of PPAR-gamma ligands on in vitro and in vivo models of COPD. Eur. Respir. J. 2013, 43:409.
19. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451.
20. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723.
21. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707.
22. Plumb J., Robinson L., Lea S., Banyard A., Blaikley J., Ray D., Bizzi A., Volpi G., Facchinetti F., Singh D. Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. PLoS One 2013, 8:e64257.
23. Renda T., Baraldo S., Pelaia G., Bazzan E., Turato G., Papi A., Maestrelli P., Maselli R., Vatrella A., Fabbri L.M., Zuin R., Marsico S.A., Saetta M. Increased activation of p38 MAPK in COPD. Eur. Respir. J. 2008, 31:62.
24. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 2004, 4:372.
25. Shaykhiev R., Krause A., Salit J., Strulovici-Barel Y., Harvey B.G., O'Connor T.P., Crystal R.G. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 2009, 183:2867.
26. Shiratsuchi H., Basson M.D. Activation of p38 MAPKalpha by extracellular pressure mediates the stimulation of macrophage phagocytosis by pressure. Am. J. Physiol. Cell Physiol. 2005, 288:C1083.
27. Singh D., Smyth L., Borrill Z., Sweeney L., Tal-Singer R. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J. Clin. Pharmacol. 2010, 50:94.
28. Soriano J.B., Sin D.D., Zhang X., Camp P.G., Anderson J.A., Anthonisen N.R., Buist A.S., Burge P.S., Calverley P.M., Connett J.E., Petersson S., Postma D.S., Szafranski W., Vestbo J. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007, 131:682.
29. Southworth T., Metryka A., Lea S., Farrow S., Plumb J., Singh D. IFN-gamma synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br. J. Pharmacol. 2012, 166:2070.
30. Tomlinson G.S., Booth H., Petit S.J., Potton E., Towers G.J., Miller R.F., Chain B.M., Noursadeghi M. Adherent human alveolar macrophages exhibit a transient pro-inflammatory profile that confounds responses to innate immune stimulation. PLoS One 2012, 7:e40348.